Small molecule · Inhibitor of tubulin · developed by BeyondSpring Pharmaceuticals
Plinabulin is an orally active diketopiperazine derivative that binds to the colchicine-binding site of tubulin, disrupting microtubule dynamics and mitotic spindle assembly. This leads to cell cycle arrest and blocks tumor cell division. It may also inhibit vascular endothelial cell growth, disrupting tumor vasculature. It is studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07361484 | Phase 3 | Non-Small Cell Lung Cancer | Not yet recruiting | BYSI |
| NCT02504489 | Phase 3 | Non-Small Cell Lung Cancer | Completed | BYSI |
| NCT05599789 | Phase 2 | Non Small Cell Lung Cancer Metastatic | Active not recruiting | BYSI |
| NCT02812667 | Phase 1 | Non-small Cell Lung Cancer Metastatic | Completed | BYSI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non Small Cell Lung Cancer MetastaticNon-squamous Non-Small Cell Lung CanceNon-Small Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the BYSI page.
See BYSI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BYSI catalysts and pipeline →